Seraxis
Germantown, US · Founded 2021 · 6 known investors
Seraxis is a regenerative medicine company developing a replacement cell therapy for insulin-dependent (Type 1) diabetes, using engineered islet cells to replace those missing in patients. It pursues scientific collaborations and licensing partnerships around its cell therapy technologies.
Founders & leadership
Seraxis was founded in 2021 by William L. Rust.
WL
William L. RustFounder
CW
Carole WelschExecutive
GY
Gi-Hyeok YangNamed on SEC filing
RA
Roy ArupNamed on SEC filing
BT
Bernie TreidlNamed on SEC filing
Board
JN
Investors · 6
Maryland TEDCOUpper Marlboro · $500K – $1.5M
TEDCOColumbia
Frazier Life Sciencesreported · 2 sourcesPalo Alto
JDRF T1D FundreportedBoston
Also in the syndicate · 2
Eli LillyPolaris Partners
Funding
SEC filings, press & company announcements$14M disclosed across 1 of 3 rounds · 2021–2025
- Undisclosed amountsecond round of venture capital financingSep 2023
Eli Lilly, Frazier Life Sciences, JDRF T1D Fund, Polaris Partners
Source ↗
▶$14MraisedFeb 2021 · 5 investors · OtherRule 506(b)
▶$14MraisedFeb 2021 · 5 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Gi-Hyeok YangDirector
- James N. TopperDirector
- Carole WelschExecutive Officer
- William L. RustExecutive Officer, Director, Promoter
- Roy ArupDirector
- Bernie TreidlDirector
- Offering amount
- $40M
- Amount sold
- $14M
- Finders' fees
- $849.5K
- Placement agents
- Capstone Headwaters
- First sale
- Jan 2021
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlap
Seres Therapeutics4 shared keywordsSeres Therapeutics is a clinical-stage biotechnology company developing therapies composed of rationally selected live bacterial consortia to treat serious diseases through modulation of the human microbiome. The company pioneered the development and FDA approval of VOWST, an oral live biotherapeutic.
Reaxbio3 shared keywordsReAx is a chemoproteomics drug discovery company using its discovery platform to develop first-in-class and best-in-class therapies for challenging protein targets. The company brings together expertise in biology, chemistry, and computation.
Companies competing with Seraxis for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Seraxis do?
- Seraxis is a regenerative medicine company developing a replacement cell therapy for insulin-dependent (Type 1) diabetes, using engineered islet cells to replace those missing in patients. It pursues scientific collaborations and licensing partnerships around its cell therapy technologies.
- Who founded Seraxis?
- Seraxis was founded by William L. Rust in 2021.
- Who are Seraxis's investors?
- Seraxis's investors include Maryland TEDCO, TEDCO, Frazier Life Sciences, JDRF T1D Fund.
- How much funding has Seraxis raised?
- Seraxis has disclosed $14M raised across 1 of its 3 known rounds.
- Where is Seraxis headquartered?
- Seraxis is headquartered in Germantown, US.